CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Neurocrine Biosciences Inc  (NBIX)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

NBIX's Revenue Growth by Quarter and Year

Neurocrine Biosciences Inc's Revenue results by quarter and year




NBIX Revenue (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December - 94.52 - -
III Quarter September 151.76 60.77 - -
II Quarter June 96.91 6.34 - -
I Quarter March 71.09 - 15.00 19.77
FY   319.76 161.63 15.00 19.77



NBIX Revenue third quarter 2018 Y/Y Growth Comment
Neurocrine Biosciences Inc achieved in the third quarter, above Company average Revenue surge of 149.72% year on year, to $ 151.76 millions.

Looking into third quarter results within Biotechnology & Drugs industry 2 other companies have achieved higher Revenue growth. While Neurocrine Biosciences Inc' s Revenue doubling of 149.72% ranks overall at the positon no. 22 in the third quarter.




NBIX Revenue ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September 149.72 % - - -
II Quarter June 1428.55 % - - -
I Quarter March - - -24.13 % -
FY   - 977.53 % -24.13 % -

Financial Statements
Neurocrine Biosciences Inc's third quarter 2018 Revenue $ 0.00 millions NBIX's Income Statement
Neurocrine Biosciences Inc's third quarter 2017 Revenue $ 0.00 millions Quarterly NBIX's Income Statement
New: More NBIX's historic Revenue Growth >>


NBIX Revenue (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December - 55.54 % - -
III Quarter September 56.6 % 858.52 % - -
II Quarter June 36.32 % - - -
I Quarter March -24.79 % - - -
FY (Year on Year)   - 977.53 % -24.13 % -




Revenue third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #3
Healthcare Sector #10
Overall #22

Revenue Y/Y Growth Statistics
High Average Low
38.92 % 4.8 % -52.66 %
(Jun 30 2018)   (Dec. 30, 2013)
Revenue third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #3
Healthcare Sector #10
Overall #22
Revenue Y/Y Growth Statistics
High Average Low
38.92 % 4.8 % -52.66 %
(Jun 30 2018)   (Dec. 30, 2013)

Revenue by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Neurocrine Biosciences Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
859.34 % 81.8 % -100 %
(Sep 30 2017)  


NBIX's III. Quarter Q/Q Revenue Comment
Neurocrine Biosciences Inc achieved in the III. Quarter 2018 below company average Revenue jump of 56.6% quarter on quarter, to $ 151.76 millions.

Within Biotechnology & Drugs industry only one company achieved higher sequential Revenue growth. While Neurocrine Biosciences Inc's Revenue growth quarter on quarter, overall rank is 43.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #6
Overall #43
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #6
Overall #43
Revenue Q/Q Growth Statistics
High Average Low
859.34 % 81.8 % -100 %
(Sep 30 2017)  


NBIX's III. Quarter Q/Q Revenue Comment
Neurocrine Biosciences Inc achieved in the III. Quarter 2018 below company average Revenue jump of 56.6% quarter on quarter, to $ 151.76 millions.

Within Biotechnology & Drugs industry only one company achieved higher sequential Revenue growth. While Neurocrine Biosciences Inc's Revenue growth quarter on quarter, overall rank is 43.


Neurocrine Biosciences Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2018)
12 Months Ending
(Jun 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
Cumulative Revenue 12 Months Ending $ 414.27 $ 323.28 $ 232.71 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 28.14 % 38.92 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 22 # 116 # 0 # 0 # 0




Cumulative Revenue growth Comment
Neurocrine Biosciences Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 149.72% year on year, to $ 414 millions if the fiscal year would have ended in Sep 30 2018.
Neurocrine Biosciences Inc's trailing twelve months Revenue growth was higher than company's average -52.66% and higher than % growth in Jun 30 2018. And, Neurocrine Biosciences Inc realized the fastest Revenue growth, in Biotechnology & Drugs industry.
But from the previous reporting period growth rate was less at 28.14 % from $323.28 millions recorded in the period from Jun 30 2018 to Sep 30 2017.
Yet it was validation of strength, while the usual sequential gain stands at 4.8%.

Neurocrine Biosciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
38.92 %
4.8 %
-52.66 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall # 0

Revenue TTM Y/Y Growth Statistics
High Average Low
-52.66 %
-52.66 %
-52.66 %
(Dec. 30, 2013)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 10
S&P 500 # 22
Cumulative Revenue growth Comment
Neurocrine Biosciences Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 149.72% year on year, to $ 414 millions if the fiscal year would have ended in Sep 30 2018.
Neurocrine Biosciences Inc's trailing twelve months Revenue growth was higher than company's average -52.66% and higher than % growth in Jun 30 2018. And, Neurocrine Biosciences Inc realized the fastest Revenue growth, in Biotechnology & Drugs industry.
But from twelve months ended Jun 30 2018 growth rate was beneth at 28.14 % from $323.28 millions achieved in twelve months ending a quarter before Harrison  L. Robinson continued.
Still it was evidence of convincing trend, while the average Q/Q TTM gain is at 4.8%.
The momentum is even stronger sequentially exhibited at 28.14 % increase from $323.28 millions in the period from Jun 30 2018 to Sep 30 2017.

Neurocrine Biosciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
38.92 %
4.8 %
-52.66 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall # 0

Revenue TTM Y/Y Growth Statistics
High Average Low
-52.66 %
-52.66 %
-52.66 %
(Dec. 30, 2013)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 10
S&P 500 # 22


You need to upgrade your Flash Player




Other Revenue Growth
Biotechnology & Drugs Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NBIX's Revenue Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for NBIX's Competitors
Revenue Growth for Neurocrine Biosciences Inc's Suppliers
Revenue Growth for NBIX's Customers

You may also want to know
NBIX's Annual Growth Rates NBIX's Profitability Ratios NBIX's Asset Turnover Ratio NBIX's Dividend Growth
NBIX's Roe NBIX's Valuation Ratios NBIX's Financial Strength Ratios NBIX's Dividend Payout Ratio
NBIX's Roa NBIX's Inventory Turnover Ratio NBIX's Growth Rates NBIX's Dividend Comparisons



Companies with similar Revenue jump for the quarter ending Sep 30 2018 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2018
Rennova Health, Inc.  256.32 %$ 256.320 millions
Aratana Therapeutics, Inc.  249.75 %$ 249.748 millions
Plx Pharma Inc.  247.79 %$ 247.789 millions
Achaogen, Inc.  246.27 %$ 246.274 millions
Northsight Capital, Inc.  238.00 %$ 237.995 millions
Innovus Pharmaceuticals, Inc.  232.31 %$ 232.305 millions
Dicerna Pharmaceuticals Inc  225.95 %$ 225.949 millions
Theravance Biopharma, Inc.  200.30 %$ 200.304 millions
Icon Plc  197.52 %$ 197.517 millions
Neurocrine Biosciences Inc  149.71 %$ 149.707 millions
Bionik Laboratories Corp.  146.60 %$ 146.605 millions
Cv Sciences, Inc.  143.25 %$ 143.255 millions
Aclaris Therapeutics, Inc.  138.01 %$ 138.012 millions
Heron Therapeutics, Inc.  130.82 %$ 130.821 millions
Quidel Corp  130.67 %$ 130.674 millions
T2 Biosystems, Inc.  122.56 %$ 122.563 millions
Mannkind Corp  118.75 %$ 118.747 millions
Pieris Pharmaceuticals, Inc.  112.49 %$ 112.492 millions
Strongbridge Biopharma Plc  111.09 %$ 111.094 millions
Invitae Corp  105.90 %$ 105.896 millions
Radius Health, Inc.  105.20 %$ 105.205 millions
Sangamo Therapeutics, Inc  99.48 %$ 99.475 millions
Progenics Pharmaceuticals Inc  97.14 %$ 97.145 millions
Array Biopharma Inc  91.32 %$ 91.320 millions
Amicus Therapeutics Inc  89.41 %$ 89.406 millions
Nephros Inc  88.21 %$ 88.210 millions
Keryx Biopharmaceuticals Inc  86.96 %$ 86.957 millions
Neos Therapeutics, Inc.  86.75 %$ 86.751 millions
Nuvectra Corp  86.64 %$ 86.635 millions
Lhc Group, Inc  85.82 %$ 85.817 millions


     
       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SBH's Profile

Stock Price

SBH's Financials

Business Description

Fundamentals

Charts & Quotes

SBH's News

Suppliers

SBH's Competitors

Customers & Markets

Economic Indicators

SBH's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071